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BACKGROUND: Non-small-cell lung cancer (NSCLC) is an aggressive disease in which vascular endothelial growth factor (VEGF) and
epidermal growth factor (EGF) are implicated in tumour growth, tumour resistance to radiation and chemotherapy, and disease
relapse. We have investigated the anti-tumoural effects of BMS-690514, an inhibitor of both vascular endothelial growth factor
receptor (VEGFR) and epidermal growth factor receptor (EGFR) signalling pathways, as a single agent and in combination with
ionising radiation (IR) on several NSCLC cell lines.
METHODS: Radiosensitisation of several NSCLC cell lines by BMS-690514 was assessed in vitro using clonogenic assay and in vivo using
nude mice.
RESULTS: In vitro studies showed that BMS-690514 alone decreases clonogenic survival of NSCLC cells lines but no potential
enhancement of IR response was observed in the combination. In tumour-bearing mice, BMS-690514 alone inhibits the growth of
NSCLC xenografts, including the T790M mutation-harbouring H1975 tumour. The concomitant combination of BMS-690514 and
radiation did not increase mice survival in comparison with treatment with IR alone. In contrast, BMS-690514 markedly enhances the
anti-tumour effect of radiation in a sequential manner on H1299 and H1975 xenografts. Immunohistochemistry revealed a qualitative
reduction in vessel area after administrations of BMS-690514, compared with vehicle-treated controls, suggesting that
revascularisation may explain the schedule dependency of the tumour-growth delay observed.
CONCLUSION: The results of association with radiation show that BMS-690514 may be a successful adjuvant to clinical radiotherapy.
These findings are of translational importance because the clinical benefits of anti-EGFR and anti-VEGFR therapy might be
schedule dependent.
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Lung cancer is a major health problem worldwide and is the leading
cause of cancer-related death for men and women (Alberg et al,
2005). Non-small-cell lung cancer (NSCLC) accounts for 85% of
lung cancer and patients typically present with locally advanced or
metastatic disease (Toschi et al, 2007). Currently, treatment options
for a patient with locally advanced lung cancer include chemother-
apy, radiotherapy, and/or surgery (Fossella et al, 2003). Unfortu-
nately, recent studies demonstrate that conventional therapies lead
to a poor outcome, with a 5-year survival rate for NSCLC that
remains at 15% (Toschi et al, 2007). Hence, the current therapeutic
challenge is to optimise non-operative strategies by incorporating
new agents into current therapeutic regimens. Targeting the tumour
vasculature with anti-angiogenic agents in combination with
radiotherapy is one current strategy (O’Reilly, 2006).
Inhibiting the epidermal growth factor (EGF) pathway is another
promising approach for improving the anti-tumoural activity of
radiation. A pivotal study reported a benefit in overall survival and
locoregional control in patients with localised head and neck
cancer who were treated with both radiation and cetuximab, a
monoclonal antibody against epidermal growth factor receptor
(EGFR), over patients treated with radiation alone (Bonner et al,
2006). Several studies demonstrated that angiogenesis and the
expression of vascular endothelial growth factor (VEGF) and other
pro-angiogenic factors and their receptors correlate with a less
favourable clinical outcome for lung cancer patients; yet clinical
trials of agents that target these pathways alone have been
disappointing (Bremnes et al, 2006). Preclinical studies suggest that
monotherapy with anti-angiogenic agents will not be sufficient for the
treatment of advanced cancer (O’Reilly et al, 1994; Boehm et al, 1997),
given that tumours typically progress before they respond to therapy
and microscopic residual disease persists even after prolonged
therapy with these agents. In clinical trials, bevacizumab, a
humanised antibody against VEGF, has shown considerable promise
and improved survival in patients with colorectal, breast, or lung
cancer when used in combinationw i t hc h e m o t h e r a p y( H u r w i t zet al,
2004; Miller et al, 2005; Sandler et al, 2006).
Several findings argue in favour of combining radiation and an
anti-angiogenic inhibitor (Senan and Smit, 2007).
Radiation induces transient tumour hypoxia, which in turn
stimulates VEGF production and vascular endothelial growth factor
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sreceptor-2 (VEGFR-2) expression (Gorski et al,1 9 9 9 ) .V a s c u l a r
endothelial growth factor protects endothelial cells from radiation-
induced cytotoxicity (Kermani et al, 2001), and vasculature damage
decreases tumour cell survival (Garcia-Barros et al, 2003). After
radiotherapy or chemoradiotherapy, as u b s e to fp a t i e n t sf a i lt oa c h i e v e
long-term local tumour control. Hypoxia or hypoxia-inducible factor-
1 expression is associated with a lower radiation response and
malignant progression in tumours of the uterine cervix, head and
neck, as well as in sarcomas, suggesting that angiogenesis could be
involved in radioresistance (Hirota and Semenza, 2006).
Preclinical studies have demonstrated enhanced radiation-
induced cell kill when anti-angiogenic therapy is combined with
radiotherapy (Lee et al, 2000; Hess et al, 2001). The normalisation
of tumour vasculature by an anti-VEGFR-2 antibody creates a
time period of increased oxygenation, during which enhanced
radiation-induced regression is observed (Winkler et al, 2004).
Combination of anti-angiogenic therapies and radiotherapy may
be effective against tumour stem cells that have self-renewing
potential, quiescence of cell cycling, and relative resistance to
growth factors (Baumann et al, 2008).
We hypothesised that targeting both the tumour and its
vasculature by VEGFR and EGFR blockade would improve lung
cancer treatment, particularly when combined with radiation
therapy. To test this hypothesis, we evaluated the feasibility of
combining radiation with BMS-690514, a potent, orally adminis-
trable inhibitor of VEGFR and EGFR tyrosine kinase activity that
was shown to have in vitro anti-tumour activity against lung
cancer cells in a panel of human NSCLC in vitro experiments
(De La Motte Rouge et al, 2007). The aim of this study was to
evaluate the effects of EGFR and VEGFR signalling inhibition on
the response to radiotherapy, to determine whether scheduling of
BMS-690514 and ionising radiation (IR) affected anti-tumour
efficacy, to assess the influence of EGFR mutation on tumour
response, and to investigate whether the effects of the treatments
were related to changes in tumour perfusion and vasculature.
In this study, we report that BMS-690514 has in vivo efficacy on a
panel of NSLCC xenografts, including those with T790M muta-
tions, conferring resistance to EGFR therapies such as Erlotinib
or Gefitinib. Furthermore, adjuvant administration of BMS-690514
was able to markedly enhance tumour response to IR in vivo in
H1299 and H1975 xenografts.
MATERIALS AND METHODS
Cell lines, culture, and treatments
A549 cells (wild-type (WT) EGFR and p53) were grown in F12-K
medium containing L-glutamine, supplemented with 10% foetal
calf serum, 100Uml
 1 penicillin-G sodium, and 100mgml
 1
streptomycin sulphate. H1299 cells (WT EGFR, inactive p53
R175H), H1650 cells (bearing a deletion in exon 19 of the EGFR
gene, that is, DE746–A750 and WT p53), and H1975 cells
(EGFR L858R/T790M and WT p53) were maintained in RPMI 1640
with GlutaMAX supplemented with 10% foetal calf serum and
antibiotics (as above). Cultures were maintained in a humidified
incubator at 371C and 5% CO2.F o rin vitro experiments, BMS-
690514 was dissolved in dimethyl sulphoxide at 50mmoll
 1 as a stock
solution and stored at  201C. For in vivo studies, BMS-690514
was prepared fresh before each administration. It was dissolved in
1,2-propanediol and Tween 80 to a final 1,2-propanediol concentration
of 40% and Tween 80 concentration of 10%.
Clonogenic survival assays
First, a clonogenic assay was performed without irradiation and
with various doses of BMS-690514 to demonstrate dose response
and calculate the concentration of BMS-690514 to inhibit 50%
of cells (IC50). To investigate the effect of BMS-690514 on the
response of cell lines to radiation, a standard clonogenic assay was
performed. Survival after radiation exposure was defined as the
ability of cells to maintain clonogenic capacity and form colonies.
Briefly, after incubation intervals of 12h with BMS-690514 at a
dose ranging from 20 to 500nmoll
 1, cells were washed and
exposed to radiation at a dose ranging from 2 to 6Gy using 200-kV
X-rays, and then cells were trypsinised, counted, and seeded for
colony formation in 35-mm dishes at 50–1000 cells per dish. After
incubation intervals of 14 days, colonies were stained with crystal
violet and manually counted. All colonies of 50 or more cells were
then counted. The survival fraction (SF) was estimated according
to the following formula: SF¼number of colonies formed/number
of cells seeded plating efficiency of the control group. All
experiments were performed in triplicate.
Assay for tumour growth in athymic nude mice
In vivo experiments were carried out at the Institut Gustave Roussy
under Animal Care license no 94-076-11 (Ministe `re de l’Agricul-
ture). Female athymic nude mice (6–8 weeks of age) purchased
from Janvier CERT (Le Genest St. Isle, France) were used. A549,
H1975, and H1299 cells were collected in exponential growth
phase and B3 10
6 cells were injected s.c. into the flank area of
6- to 8-week-old female athymic nude mice on day 0. When
tumours reached the appropriate size, mice were randomised into
groups of six mice each and treated.
Three separate animal experiments were performed:
(a) BMS-690514 alone: Mice bearing tumours with a volume of
75–150mm
3 were randomly assigned to receive BMS-690514
(30mgkg
 1day
 1) or vehicle (1, 2-propanediol and Tween 80 in
saline water). Treatment was administered once daily by oral gavage
for 5 days.
(b) BMS-690514þIR: For BMS-690514 and radiation studies,
mice bearing established tumours of a volume of 75–150mm
3
were randomised into groups of six to orally receive either vehicle
or BMS-690514 (30mgkg
 1 per os quaque die (every day) 5,  1
week) once daily for the duration of the experiment. BMS-690514
or vehicle was administered with or without irradiation (6Gy in a
single administration on day 3). Localised irradiation was
administered at a dose rate of 0.85Gymin
 1 using mouse jigs.
(c) IRþadjuvant BMS-690514: For H1299 and H1975 xeno-
grafts, BMS-690514 was given the first day after IR at a dose of
6Gy, and from day 2 to day 12 according to a sequential schedule.
Mice were weighed, and tumour size was measured twice a week
with an electronic caliper. Individual mice were followed up over
30 days after the beginning of the treatment. Tumour volume
was estimated from two-dimensional tumour measurements using
the following formula:
Tumourvolume ¼ lengthðmmÞ width
2 ðmm
2Þ=2
In each group (six mice per group), the relative tumour volume
was expressed as the Vt/Vo ratio (Vt as the mean tumour volume
on a given day during the treatment and Vo as the mean tumour
volume at the beginning of the treatment).
The experimental end point was taken as the time for the
tumour to reach a relative tumour volume of five times that at the
initiation of therapy (RTV5). When tumours reached RTV5, mice
were killed. Overall survival was calculated using the Kaplan–
Meier method. Growth delay was calculated by subtracting the
average time for control tumours to grow five-fold in volume from
the time required for treated tumours to increase in volume by the
same amount from the first day of treatment.
Immunohistochemistry
Histological assessment was carried out to evaluate the effects of
BMS-690514 on tumour vasculature. Three animals were killed
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and, after fixing them in Finefix (Milestone, Italy), paraffin
sections (4-mm thick) were prepared. After xylene treatment and
rehydration, immunohistochemistry of anti-CD34-positive murine
endothelial cells (HyCult Biotechnology b.v., Uden, The Nether-
lands) was performed. Heat-induced epitope retrieval was achieved
with Tris–EDTA (pH 8) at 981C for 40min. Endogenous
peroxidase activity was quenched by treatment with 3% H2O2 for
10min. The sections were placed in coverplates (Shandon,
Pittsburgh, Pennsylvania, USA) and incubated with blocking
serum Biogenex wash buffer (1:10 dilution; San Ramon, CA,
USA) for 10min. This step was followed by incubation with anti-
mouse CD34 (1:20 dilution) diluted in blocking serum (1:10
dilution) for 1h. Slides were then incubated with a rabbit anti-rat
(1:400) (Southern Biotechnology, Birmingham, AL, USA) diluted
in blocking serum (1:10 dilution). The following step was performed
using a Rabbit PowerVision kit (ImmunoVision Technologies,
Burlingame, CA, USA) for 20min and diaminobenzidine for 10min.
Slides were counterstained with Mayer’s hematoxylin and mounted
with Pertex. Tumour necrosis was assessed by light microscopy. The
number of microvessels per field was scored by averaging five field
counts of three individual tumours for each group.
X-ray irradiation
A 200-kV X-ray irradiator was used at a dose rate of 0.85Gymin
 1.
For in vivo irradiation, radiation was given using mouse jigs
designed to expose only the tumour bed to radiation.
Statistical analysis
All descriptive statistics, including mean±s.d., were performed.
A Student’s t-test was used to evaluate differences between the
control group and each treatment group in all in vitro studies.
Kaplan–Meier curves were used for in vivo experiments and the
log-rank test was used for statistical comparisons.
RESULTS
The VEGFR and EGFR inhibitor, BMS-690514, decreases the
survival of NSCLC cells lines, regardless of the EGFR mutational
status at submicromolar concentrations. The effect of BMS-690514
on the proliferation of four NSCLC cell lines was determined by
clonogenic assay after a 12-h incubation with BMS-690514 at doses
ranging from 5 to 500nmoll
 1. Clonogenic surviving fraction
was significantly reduced in all cell lines including the EGFR
mutation (T790M)-harbouring cell line (H1975), a mutation
that confers resistance against erlotinib (Yun et al, 2008). This
effect was obtained at an IC50 value of B20nmoll
 1 for A549
and H1975 cell lines; at B10nmoll
 1 for the H1650 cell line; and at
B40nmoll
 1 for the H1299 cell line (Figure 1), and was dose
dependent. These data are consistent with those reported by
a previous study that showed that these concentrations led to a
significant decrease in EGFR phosphorylation (De la Motte Rouge
et al, 2007).
IR cell killing is not affected by BMS-690514
No potential in vitro enhancement of radiation cell killing
was observed with BMS-690514 in NSCLC cells at a dose of
20 (Figure 2) or 500nmoll
 1 (data not shown). Clonogenic
survival was not different in the four NSCLC cell lines treated with
BMS-690514, radiation, or both.
BMS-690514 alone inhibits growth of NSCLC xenograft
regardless of EGFR mutational status
Continuous oral dosing of A549, H1299, and H1975 tumour-
bearing mice with BMS-690514 for 5 days resulted in tumour
growth inhibition. Figure 3A shows that BMS-690514 increases
survival in A549 tumour-bearing mice (P¼0.02), H1299 tumour-
bearing mice (P¼0.02), and H1975 tumour-bearing mice (P¼0.1),
compared with mice treated with vehicle. The time taken to
reaching a relative A549 tumour volume equivalent to five times
that at the start of the treatment (RTV5) was 40±12 days with
BMS-690514 compared with 22±11 days with vehicle (P¼0.02).
Similar data were observed for H1299 tumour-bearing mice: RTV5
was 17±3.5 days with BMS-690514 compared with 9±1.2 days
with vehicle (P¼0.02). RTV5 was 23±5 days in H1975 tumour-
bearing mice administered BMS-690514 compared with 14±4 days
for mice treated with vehicle (P¼0.15).
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Figure 1 Anti-proliferative effect of BMS-690514 on NSCLC cell lines. A549, H1299, H1975, and H1650 cells were treated with the indicated
concentrations of BMS-690514 for 12h and then clonogenic survival assay was performed. Colonies were counted 14 days later. Clonogenic survival of
cultures treated with BMS-690514 is normalised to that of untreated cells. One representative experiment is shown here.
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Figure 2 Anti-proliferative effect of BMS-690514 combined with radiation on NSCLC cell lines. H1975, H1650, H1299, and A549 cells were incubated
with (-’-) or without (   E   ) BMS-690514 (20nmoll
 1) for 12h and then treated with radiation at a gradual dose; clonogenic assay was then
performed. Colonies were counted 14 days later. Clonogenic survival of cultures treated with radiation is normalised to that of unradiated cells. Columns
represent mean of triplicate wells and bars represent s.d. values.
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Figure 3 BMS-690514 does not enhance the efficacy of radiotherapy in NSCLC xenografts in concomitant sequence. (A) Effects of BMS-690514,
radiation (RT), or both on RTV5 (days). RTV5 was calculated as the time for the tumour to reach a relative tumour volume that is five times of that at the
initiation of therapy. Kaplan–Meier survival curves of mice inoculated with A549 cells (B), H1299 cells (C), and HT1975 cells (D) treated with vehicle (—)
or BMS-690514 (....); 30mgkg
 1; p.o.; (from day 1 to day 5) alone or IR alone (--); 6Gy on day 3 or both (--), (concurrent sequence). n¼6 per group.
Statistical analysis: (B) A549: combination vs IR, P¼0.12; combination vs BMS-690514, P¼0.96; (C) H1299: combination vs IR, P¼0.82; combination vs
BMS-690514, P¼0.08; (D) H1975: combination vs IR, P¼0.10; combination vs BMS-690514, P¼0.08.
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anti-tumour activity with radiation
To evaluate the potent interaction between BMS-690514 and
radiation, tumour-bearing mice were treated with either
BMS-690514 or radiation, or both, in concomitant schedule.
The potential of BMS-690514 to enhance the efficacy of
radiotherapy in NSCLC xenografts was first investigated in a
concurrent schedule, in which 30mgkg
 1 BMS-690514 was given
orally once a day from day 1 to day 5 and 6-Gy radiation
was administered at day 3. No increase in survival was observed
in mice treated with both treatments (Figure 3B–D).
While on a concurrent schedule, no enhancement of radiation
was observed; BMS-690514 markedly enhances the anti-tumour
effect of radiation in a sequential manner (Figure 4). H1299
xenograft-bearing mice, treated with a 30-mgkg
 1 oral dose of
BMS-690514 from day 2 to day 12 after the completion of radiation
(6Gy at day 1), exhibited a significant increase in survival (median
survival¼20 days), compared with mice treated with radiation
alone (median survival¼13.5 days, P¼0.004) or BMS-690514
alone (median survival¼14 days, P¼0.07). Furthermore, the
association leads to an increase in time to reach RTV5 as
compared with mice treated with BM-690514 alone or radiation
alone (Figure 5B). The association was well tolerated (Figure 5C).
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*
S
u
r
v
i
v
a
l
Vehicle
IR
BMS
IR+BMS
30
20
25
5
10
15
0
T
i
m
e
 
t
o
 
r
e
a
c
h
 
R
T
V
5
 
(
d
a
y
s
)
Time (days)
Mice weight variation
W
e
i
g
h
t
 
(
g
)
Control
IR
BMS-690514
BMS-690514+IR
35
40
5
10
15
20
25
30
0
Days
1.0
0.8
0.4
0.0
0.6
0.2
Vehicle BMS+IR BMS IR
12 6 21 16 11 6
02 5 20 15 10 5
Figure 4 BMS-690514 enhances the efficacy of radiotherapy in NSCLC xenografts in sequential manner. (A) Kaplan–Meier survival curves of H1299
tumour-bearing mice treated with vehicle (.-.-.-.) or BMS-690514 (.-.-.-.); (30mgkg
 1 p.o. from day 2 to day 12) alone or with IR alone (--); (6Gy
on day 1), or with both (--); adjuvant sequence. n¼6 per group. Statistical analysis: combination vs vehicle, P¼0.002; combination vs IR; P¼004;
combination vs BMS-690514, P¼0.007; IR vs vehicle, P¼0.005; BMS-690514 vs vehicle, P¼0.01. (B) Influence of BMS-690514 (30mgkg
 1, p.o. from day
1 to day 12) and/or IR treatment on time to achieve RTV5. Data are shown as mean values (±s.d.) with n¼6 per group. *, Po0.05; (Student’s t test); RTV5
was calculated as the time for the tumour to reach a relative tumour volume five times of that at the initiation of therapy. Growth delay was calculated by
subtracting the average time for control tumours to grow five-fold in volume from the time required for treated tumours to increase in volume by the same
amount from the first day of radiation. (C) Mice weight in untreated and treated mice.
BMS-690514 Vehicle
Figure 5 BMS-690514 induces a trend towards reduced tumour perfusion. CD-34 staining of perfused vessels in a tumour treated with one daily fraction
of vehicle or BMS-690514 (30mgkg
 1day
 1 for 3 days).
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 1
BMS-690514 treatment for 12 days induced a mean body weight
loss of 7%±2. This was not different from that induced by 12 days
of treatment with 30-mgkg
 1 BMS-690514 alone. These results
were also observed for H1975 xenograft-bearing mice: mice
treated with a 30-mgkg
 1 oral dose of BMS-690514 from day 2 to
d a y1 2a f t e rc o m p l e t i o no fr a d i a t i o n( 6 G ya td a y1 )e x h i b i t e da
significant increase in survival (median survival¼20 days) compared
with mice treated with radiation alone (median survival¼14 days,
P¼0.005) or BMS-690514 alone (median survival¼9d a y s ,P¼0.05).
BMS-690514 decreases vascularisation in xenografts
As shown in Figure 5, BMS-690514 could decrease vasculari-
sation in H1299 xenografts as compared with untreated H1299
xenografts, suggesting an anti-angiogenic effect of BMS-690514.
After 3 days of BMS-690514 administration (30mgkg
 1day
 1), the
proportion of tumour vessels seemed to be lesser than that in
vehicle-treated controls and a qualitative reduction in CD34-
positive vessel area was observed.
DISCUSSION
Patients with locally advanced NSCLC have a poor outcome with a
5-year survival rate of 15%. As chemoradiotherapy for these
patients has a modest impact on survival, associations of new
targeted therapies with radiation are needed. As EGFR and VEGFR
expressions were shown to be important for NSCLC cancer, there
is significant rationale behind the treatment of these tumours with
BMS-690514. In this study, we showed that the initial inhibition of
EGFR and VEGFR by a small inhibitor of tyrosine kinase used as a
stand-alone treatment could induce an anti-tumoural effect on
several NSCLC xenografts. Chronic administration of BMS-690514
(30mgkg
 1day
 1) is well tolerated in athymic mice (Figure 4C)
and produces significant inhibition of tumour growth (Figure 3).
These results are consistent with previous in vitro data that
reported a cytotoxic effect on NSCLC cell lines (De la Motte Rouge
et al, 2007). Interestingly, these effects were observed even on
T790M-harbouring tumours that confer resistance to an EGFR
inhibitor such as Erlotinib (Figure 3). We then showed that this
double tyrosine kinase blockade could enhance the anti-tumoural
effect of radiotherapy in a sequential manner (Figure 4).
We observed that BMS-690514 had no effect on radiation
response in in vitro assays but led to a marked tumour growth
delay when used sequentially with IR in vivo. Although no
radiosensitisation effect was observed in the concomitant schedule,
a strong synergistic activity was shown in adjuvant sequence
(Figure 4). The positive interaction observed when BMS-690514 is
used as an adjuvant to radiotherapy supports an important role for
VEGF-mediated pathway in the tumour response to radiotherapy
in vivo. The anti-tumour activity of radiation could be influenced
by many factors, such as intrinsic tumour radiosensitivity, altered
capacity for DNA repair, and the VEGF pathway. Some findings
have shown that the induction of VEGF by irradiation contributes
to the protection of tumour blood vessels from radiation-mediated
cytotoxicity, and thereby to tumour radioresistance (Gorski et al,
1999). Furthermore, radiation therapy resulted in an increased
expression of both VEGFR-2 and EGFR in lung tumours, leading to
tumour proliferation and survival (Shibuya et al, 2007).
Adjuvant inhibition of angiogenesis, that is, application of anti-
angiogenic compounds after radiotherapy has been completed,
is suggested to prolong the dormancy of residual tumour cells by
inhibiting the formation of the new blood vessels that are required
for regrowth of tumour cells that survived irradiation (Kerbel,
2008). Vascular endothelial growth factor seems to be expressed as
the principal pro-angiogenic factor for early-stage cancers (Ferrara,
2004), and tumour progression, including progression after curative
treatment, is often associated with an altered expression of other
pro-angiogenic factors. This concept is supported by some studies
that show that tumour blood flow increases after irradiation,
probably contributing to the regrowth of cancer because certain
cells survived irradiation (Hori et al,2 0 0 8 ) .
The questions of optimal scheduling have been addressed in
limited studies combining radiotherapy with a number of anti-
angiogenic agents (Williams et al, 2004; Dings et al, 2007; Shibuya
et al, 2007) A study using concomitant PTK787/ZK222584 failed
to show enhancement over radiotherapy alone, and study
results showed that drug therapy after irradiation was optimal (Zips
et al, 2005). A study with Vandetanib reported that when radiation
therapy is combined concomitantly with VEGFR2 and EGFR
blockade, a significant enhancement of anti-angiogenic, anti-
vascular, and anti-tumour effects is seen in an orthotopic model of
lung cancer (Kerbel, 2008). Another previous study with Vandetanib
in a Calu-6 tumour model showed that sequential administration
with Vandetanib after radiotherapy was optimal, although con-
current treatment with Vandetanib and radiotherapy was better than
treatment with either alone (Williams et al, 2004). Other tyrosine
kinase inhibitors with anti-angiogenic effects, such as SU5416 (a
VEGFR inhibitor) and SU6668 (an inhibitor of VEGF, fibroblast
growth factor, and platelet-derived growth factor receptors), also
enhance the anti-tumour effects of fractionated irradiation indepen-
dent of drug sequencing (Ning et al, 2002).
The radiopotentiating effect of BMS-690514 was reduced when
BMS-690514 was administered concomitantly with radiation as
compared with a sequential schedule. After 3 days of BMS-690514
administration (30mgkg
 1day
 1), the proportion of abnormal
tumour vessels seemed to be lesser than that in vehicle-treated
controls and a qualitative reduction in CD34-positive vessel area
was observed (Figure 5). Hence, this reduced perfusion could
induce an increase in hypoxic fraction within treated tumours that
could potentially affect the tumour response to radiotherapy when
an anti-angiogenic compound is administered before or during
radiotherapy. The reduced perfusion observed as a consequence of
BMS-690514 administration may inhibit this effect, thereby
limiting the potential for reoxygenation and the efficacy of the
fractionated radiotherapy used. These observations are consistent
with previous reports of reduced tumour vascular permeability/
perfusion after Vandetanib treatment, a VEGFR and EGFR
inhibitor (Checkley et al, 2003).The results from the study with
Vandetanib showing that the schedule of concomitant association
of Vandetanib results in poor enhancement of radiation were
attributed to decreased perfusion in the concurrent schedule such
that radiotherapy was impaired (Williams et al, 2004). However,
the effect of the sequence could be related to EGFR blockade, as
these results were not observed with SU5416 (a VEGFR inhibitor)
and SU6668 (an inhibitor of VEGF, fibroblast growth factor, and
platelet-derived growth factor receptors).
The type of cell lines tested may also influence the sequence
dependency of the findings with concurrent irradiation, as
comparisons between models strongly and weakly expressing EGFR
show that EGFR ‘strong’ cell lines exhibit both increased tumour
growth delay after exposure to IR and a dual EGFR–VEGFR2
inhibition with paradoxical superiority of concomitant versus
adjuvant sequencing in EGFR ‘weak’ cell lines (Gustafson et al, 2008).
A preclinical evaluation of the combination of ionising radiation
and 4h after the last radiation dose showed that a vascular disrupting
agent, ZD6126, combined with the anti-EGFR Gefitinib did enhance
in vivo tumour growth delay in NSCLC models (Raben et al, 2004).
Altogether, the sequence dependency effects of the combination
of anti-vascular agents and anti-EGFR inhibitors on ionising
radiation may differ depending on models and drugs. However,
there is consistency regarding the beneficial effect of adjuvant
treatment. Our data are in line with these findings. Given the fact
that this type of scheduling offers minimal toxicity hazard
compared with concurrent treatment, adjuvant treatment should
be the optimal treatment in a clinical setting.
Combination therapy of radiation and BMS-690514
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sIn conclusion, these data show that inhibition of both the VEGF
and EGFR pathways demonstrates efficacy in NSCLC xenografts
and that combining such agents with radiation could improve the
anti-tumour activity of radiation alone. However, scheduling
seems to be an important factor to be taken into account
to establish optimal effect. This study supports the development
of BMS-690514 in NSCLC as an adjuvant to radiotherapy in a
clinical.
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